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We have observed marked depletion of epidermal den-
dritic cells, defined by monoclonal antibodies directed 
against HLA-DR (!a-like) and T6 antigens, after allo-
geneic bone marrow transplantation. To more precisely 
characterize this observation, we examined a total of 39 
sequential biopsies from 15 patients both before and 
after allogeneic bone marrow transplantation. Profound 
depletion of HLA-DR and T6-positive epidermal den-
dritic cells was observed early after transplantation (1-
4 weeks) , followed by gradual and variable repopula-
tion. Transmission electron microscopy confirmed ab-
sence of dendritic cells in selected biopsies. Depletion of 
dendritic cells did not appear to be related to develop-
ment of clinical or histologic evidence of graft-versus-
host disease, suggesting that depletion may relate to 
pretransplant conditioning regimens. The rate of return 
of these cells, however, may be influenced by the pres-
ence or persistence of clinical disease. Repopulation of 
epidermal dendritic cells after initial depletion in bone 
marrow transplantation represents a human model rel-
evant to studies concerned with the origin and kinetics 
of Langer hans cells. 
Epidermal dendritic cells (EDC) are specialized mononuclear 
cells important in accessory function, such as antigen presen-
tation, in the cutaneous immune response [1]. Most EDC are 
Langerhans cells, characterized by structural (Birbeck gran-
ules) [2], enzymehistochemical [3), and immunologic markers 
[4-8]. Similar cells devoid of Birbeck granules (indeterminate 
cells) have morphologic and immunologic features akin to 
Langer hans cells [9,10], and also represent a component of the 
EDC population. Although considerable knowledge is available 
concerning the structure, antigenic characteristics, and func-
tion of EDC [1,11- 13], little is known of their origin or kinetics. 
Murine models used to examine repopulation of EDC in 
chimeric animals have provided compelling evidence that these 
cells are derived from the bone marrow [14-16]. We and others 
have recently observed that the antigen T-200, common to 
hematopoietic progenitor cells, is also present on human Lan-
gerhans cells, suggesting bone marrow origin of EDC in humans 
[7,17] . Precise methods to prove these observations in human 
clinical settings have, until now, been unavailable. 
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Abbreviations: 
BMT: bone marrow transplantation 
DAB: 3,3' -diaminobenzidine 
EDC: epidermal dendritic cells 
GVHD: graft-versus-host disease 
MHC: major histocompatability 
PBS: phosphate-buffered saline 
SCIDS: severe combined immunodeficiency syndrome 
Recently, several investigators have observed depletion of 
T6-positive EDC in acute graft-versus-host disease (GVHD) 
[18,19]. It is unclear, however, (i) whether these observations 
are attributed to diminished T6 antigen expression or true cell 
depletion, and (ii) whether these events are consequent to bone 
marrow transplantation (BMT) itself, the radiation and chemo-
therapy pretransplant conditioning regimen, or the subsequent 
development of clinical disease. In the course of studying hu-
man GVHD, we observed, using immunologic and ultrastruc-
tural methods, a profound depletion, followed by variable re-
population, of EDC. Depletion early after BMT appeared to be 
independent of clinical or histologic evidence of GVHD, sug-
gesting that factors other than the development of clinical 
disease are responsible for this event. Eventual repopulation of 
EDC, on the other hand, may vary according to the presence 
or persistence of GVHD. EDC repopulation after allogeneic 
BMT provides an important clinical model whereby the origin 
and kinetics of human Langer hans cells may be more precisely 
understood. 
MATERIALS AND METHODS 
Patients 
Punch biopsies (4 mm) of upper arm or trunk skin from 15 patients 
were obtained using a Keyes punch instrument with 1% Xylocaine 
without epinephrine; one skin biopsy (from patient #14) was obtained 
at autopsy 6 h after death. Previous studies in our laboratory have not 
disclosed significant site-related differences in EDC from these ana-
tomic regions. Pretransplant biopsies (just before conditioning regie 
men) were obtained in 4 patients and at least 2 sequential biopsies 
were obtained in all but 2 patients (39 total specimens, see Table I) . 
Nine male and 6 female patients were studied, and ages ranged from 
16 months to 37 years. Twelve patients had previously treated leuke-
mias; 2 had aplastic anemia; and 1 had severe combined immunodefi-
ciency syndrome (SCIDS). All patients with leukemia received frac-
tionated total-body irradiation (1080 or 1200 rads) and chemotherapy 
(cyclophosphamide and cytosine arabinoside) during the week prior to 
transplant; the 3 nonleukemic patients received only antithymocyte 
serum and cyclophosphamide before transplant; one patient (#6) re-
ceived anti-T-cell monoclonal antibodies after transplant, and patients 
#4, 6, 12, and 14 had their donor marrow treated in vivo with anti-T-
cell monoclonal antibodies and complement to deplete mature T lym-
phocytes from the infusate. Clinical grades of GVHD were determined 
according to an established protocol [20]. Five normal skin specimens 
obtained from patients undergoing routine reduction mammoplasties 
and abdominoplasties served as controls. 
Tissue Preparation 
Tissue was immediately subdivided into 3 portions with a sharp 
blade. One portion was placed in 10% neutral buffered formalin and 
prepared routinely for paraffin histology. Specimens evaluated by this 
method were graded using histologic parameters as previously described 
[21]. A second portion was frozen in Optimum Cutting Temperature 
(OCT) compound (Ames Co., Division of Miles Laboratories, Naper-
ville, Indiana) by suspension in isobutane cooled with dry ice. Prior to 
immunoperoxidase staining, specimens were sectioned on a cryostat at 
4-l'm intervals and mounted on gelatin-coated glass slides. The third 
portion was immersed in Karnovsky's II solution [22] in preparation 
for further processing for transmission electron microscopy. 
Monoclonal A.ntibodies 
210 
The monoclonal antibodies used were anti-HLA-DR, anti-Leu 1 and 
anti-Leu 4 (Becton Dickinson, Mountain View, California), and anti-
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TABLE I. Patient population 
Case Sex Age (yrs) Diagnos is Pre-BMT treatment• 
1 M 28 ALL FTBI, CT 
2 M 13 AML FTBI, CT 
3 M 23 CML FTBI, CT 
4 F 22 AML FTBI, CT 
5 M 37 Pre-L FTBI, CT 
6 M 17 mos Juvenile CML FTBI, CT 
7 F 27 AML FTBI, CT 
8 M 27 AML FTBI, CT 
9 F 19 AM FTBI, CT 
10 M 16 AA CT, ATS 
11 M 16 CML FTBI, CT 
12 F 16 mos SCIDS CT, ATS 
13 F 34 ALL FTBI, CT 
14 M 32 AML FTBI, CT 
15 F 5 AA CT, ATS 
• Immediately prior to BMT; not for primary disorder. 
Key: AA: aplastic anemia 
AM: acute myelofibrosis 
ALL: acute lymphocytic leukemia 
AML: acute myelocytic leukemia 
ATS: antithymocytic serum 
CML: chronic myelocytic leukemia 
CT: chemotherapy 
FTB!: fractionated total-body irradiation 
Pre-L: preleukemia 
SCIDS: severe combined immunodeficiency syndrome 
T6 (Ortho Diagnostic Systems, Raritan, New Jersey) . Anti-HLA-DR 
[23] reacts with the nonpolymorphic region of human !a-like antigens. 
Anti-T6 reacts with 70% of thymocytes, Langerhans cells, indetermi-
nate cells, and histiocytosis-X cells, but not with peripheral T cells 
[5,10,24,25] . Anti-Leu 1 and anti-Leu 4 (used as primary antibody 
controls) react with the majority of peripheral E-rosette-positive cells 
but not with Langerhans cells or indeterminate cells. 
I mmunoperoxidase Procedure 
The technique employed primary monoclonal antibodies, a biotiny-
lated secondary antibody, and an avidin-biotin-horseradish peroxidase 
complex (Vector Laboratories Inc., Burlingame, California). This tech-
nique has been described previously in detail [5]. All sections were 
stained with 3,3 '-diaminobenzidine (DAB) (Sigma, St. Louis, Missouri) 
for 60 s and rinsed in phosphate-buffered saline (PBS) to terminate 
the staining reaction . They were then examined with the light micro-
scope. 
Quantification of CelL~ 
Positively stained EDC were enumerated per linear millimeter of 
epidermis with the aid of an ocular grid micrometer as previously 
described [26]. Only cells containing nuclei (visible as a central zone 
lacking reactivity) were enumerated; dendrites were not counted. 
Transmission Electron Microscopy 
Selected biopsy specimens (Table II) were immersed immediately in 
Karnovsky's II fixative and finely minced with a sharp blade into 1-
mm2 cubes. After 5 h of fixation, the tissue was rinsed in 0.1 M sodium 
cacodylate buffer (pH 7.4) for 2 h and then postfixed with agitation in 
1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) . After 2 15-
min rinses with buffer, the tissue was dehydrated in graded ethanol 
solutions and then in propylene oxide and finally embedded in low-
viscosity embedding medium (Spurr). One micrometer-thin sections 
were cut on a Porter Blum MT-2 ultramicrotome, stained with toluidine 
blue, and examined by light microscopy. Ultrathin sections were then 
prepared from selected fields, stained with uranyl acetate and lead 
citrate, and examined using a JEOL JSM 100S transmission electron 
microscope. Multiple fields (over 100/biopsy) representing a total of 
1.5- 2.0 linear mm of epidermis were viewed to document absence of 
epidermal Langerhans cells. These cells are easily detected when con-
trol skin was subjected to identical study. 
RESULTS 
Of the 15 patients studied, 11 developed clear evidence of 
acute GVHD within the first month after BMT (diffuse mor-
billiform to erythrodermic cutaneous eruptions, abnormal liver 
TABLE II . Number of T6- and !a-positive EDC per linear millimeter 
in BMT patients 
Patient# 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Days 
post- BMT 
20 
49 
88 
41" 
55" 
33 
Pre" 
14" 
35" 
55" 
15 
25 
32 
52 
29" 
40" 
61 
79 
20 
34 
49 
Pre 
14 
32 
57 
61 
149 
292 
292 
18" 
96 
Pre" 
14" 
48" 
5 
Pre 
16 
Clinical or 
histologic T6•/ mm 
GVHD 
Yes 2. 1 
11.7 
14.2 
Yes 3.7 
7.1 
Yes 13.9 
No 19.9 
0.3 
17.7 
36.3 
Yes 0.6 
1.3 
3.4 
7.7 
Yes 0.4 
1.0 
2.9 
4.3 
Yes 0 
0 
0 
Yes 3.1 
0.9 
7.3 
Yes 0 
Yes 7.6 
Yes 11.3 
17.7 
16.3 
Yes 0 
11.3 
No 3.8 
0 
4.2 
No 0.5 
No 10.1 
12.3 
• Transmission electron microscopy performed. 
Ja•/ mm 
0.3 
3.5 
4.1 
1.9 
7.9 
10.8 
12.7 
0 
10.8 
9.5 
0.4 
0.9 
NA 
5.1 
0.5 
0.5 
0.0 
5.2 
0 
0 
0 
5.0 
0 
2.8 
NA 
NA 
0 
9.0 
10.2 
0 
4.6 
1.1 
0 
0.8 
0.04 
3.5 
4.4 
Key: NA: not applicable (generally due to number of exocytotic, !a-
positive cells in epidermis) 
Pre: pretreatment biopsy 
function tests and/or diarrhea). All posttransplant biopsies 
during this period and subsequently in these patients were of 
lesional skin, and all showed evidence of acute (10 patients) or 
early chronic (1 patient) GVHD. Because mild alterations in 
epidermal maturation may relate to toxic effects of pre-BMT 
radiation and chemotherapy [27], only biopsies with pro-
nounced epidermotropism of mononuclear cells, satellitosis, 
and basal cell layer vacuolization with melanin pigment incon-
tinence were diagnosed histologically as consistent with acute 
GVHD. Four patients (#4, 13, 14, and 15) had no clinical 
evidence of G VHD at the time of biopsy and their skin was 
histologically within normal limits. 
All pretransplant biopsies showed variable numbers of T6-
and !a-positive EDC (T6 = 3.1-19.9/mm; Ia = 1.1-12.7/mm); 
these results were similar to the control subjects evaluated in 
this and in previous studies [26]. However, dramatic depletion 
of EDC was observed during the first to the fourth week 
posttransplant (Table II; Figs 1, 2). During this period patients 
frequently had no detectable EDC that were immunoreactive 
with anti-T6 or anti-Ia antibodies. Sequential biopsies revealed, 
however, gradual repopulation of EDC in all but one individual 
(#7) during the second and third months after transplant. 
Depletion of EDC was independent of clinical or histologic 
grades of GVHD and of posttransplant immunotherapy. Of 
patients who did not develop clinical or histologic evidence of 
GVHD (#4, 13, 14, and 15), all who had received pretransplant 
fractionated total-body irradiation showed EDC depletion post-
BMT. The one patient who did not receive radiation (#15) 
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FIG 1. lmmunoperoxidase staining of EDC using anti-T6 antibody of patients without (a-c) and with (d- f) acute GVHD. Skin biopsies 
obtained before allogeneic BMT (a and d) show T6-positive dendritic cells within the epidermis. Biopsies 14 days after tranplantation (band e ) 
show absence of T6-positive dendritic cells in both patients. By days 35 (c) and 32 (f) posttransplant, both patients show repopulation of T6· 
positive cells. X 400. 
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FIG 2. Graph of number of T6-positive (T6+) EDC per linear mm 
of epidermis vs time. Sequential biopsies reveal marked depletion of 
T 6+ cells during the second to fourth weeks after transplantation, 
foll owed by variable repopulation in all patients serially examined after 
day 31. Solid lines represent patients with clinical and histologic 
evidence of GVHD; broken lines represent patients without evidence of 
GVHD. 
showed no significant changes in the number of EDC posttrans- . 
plant . 
Repopulation of EDC was extremely variable after initial 
depletion . Patients with less severe clinical GVHD (grade 1- 2) 
generally showed rapid repopulation, whereas those with more 
severe GVHD (grade 3- 4) showed delayed and more gradual 
repopulation. One patient (#7) fai led to show repopulation of 
EDC; interestingly, this patient exhibited transient loss of 
engraftment around the time of the third biopsy (day 49) . 
Two of the 4 patients who did not develop GVHD were 
sequentially biopsied during the first 2 months after transplant 
(#4 and 13). Both showed rapid repopulation of EDC after 
initial depletion; the rate of repopulation in patient #4 was 
more rapid than that of most patients with GVHD. 
Transmission electron microscopy confirmed normal epider-
mal Langerhans cells in pre-BMT biopsies and absence of 
epidermal Langerhans cells in selected biopsies post-BMT (Ta-
ble II). Examination of multiple fie lds (1.5-2.0 linear mm of 
epidermis) were performed to ensure absence of these cells in 
the tissue examined. Langerhans cells appeared normal after 
epidermal repopulation in the cases studied by this technique. 
During repopulation, numerous cells with morphologic features 
of indeterminate cells and Langer hans cells depleted of Birbeck 
granules were observed in the superficial dermis (report in 
preparation). 
Although numerous Leu 1 and Leu 4-positive cells were 
present in the dermal infiltrates at certain stages of most 
biopsies, immunoreactivity with these antibodies was not ob-
served in EDC. 
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DISCUSSION 
We have demonstrated, using correlative immunocytochem-
ical and ultrastructural techniques, marked depletion and re-
population of EDC after allogeneic human BMT. Although the 
precise mechanism of these cellular events is unclear, our data 
suggest that (i) depletion of EDC after BMT results from a 
true decrease in cell number, rather than diminished expression 
of antigens used for their detection; (ii) this depletion does not 
depend upon the simultaneous development of acute GVHD· 
(iii) EDC repopulat ion occurs at variable rates which poten~ 
tially correlate with the level or persistence of clinical GVHD 
or the occurrence of graft failure; and (iv) the setting of human 
BMT may serve as an important model whereby hypotheses 
concerning the origin and kinetics of EDC can be tested. 
The idea that EDC, with antigen-presenting capabilities, may 
be important in the pathogenesis of GVHD derives from animal 
models and studies of human disease, suggesting a role for 
cellular immune mechanisms in this disorder (28-31]. Recent 
in situ observations of apparent depletion of EDC in acute 
GVHD [19,30,32] have renewed interest in this hypothesis. 
Most EDC, unlike other normal epidermal cells (exclusive of 
acrosyringeal epithelium), express class II major histocompat-
ability (MHC) antigens, and therefore are themselves potential 
targets of alloreactive T cells [33,34] . To our knowledge, prior 
to this report, no detailed studies of the sequential immunologic 
and morphologic changes in EDC populations after BMT have 
been documented, and most previous observations have been 
limited only to patients and experimental animals who devel -
oped GVHD [19,30,32]. Furthermore, correlative ultrastruc-
tural observations have not been performed to determine 
whether EDC are truly depleted, as opposed to diminished 
expression of surface antigens used for their detection. 
In this study, we demonstrate conclusive depletion of EDC 
that is independent of the development of GVHD after BMT. 
EDC depletion in the post-BMT setting, therefore, should not 
serve as a diagnostic parameter in assessing presence or absence 
of GVHD . Whether or not EDC are essential to the initiation 
of cutaneous GVHD in humans cannot be determined from our 
data. However, absence of these important accessory cells after 
BMT is likely to contribute to abrogated immune defenses 
typical of the posttransplant period. Studies of skin after BMT 
should foster understanding of the nature of depletion of EDC 
(e.g., local destruction vs exodus) and whether this depletion is 
a consequence of pretransplant radiation, a phenomenon well 
documented in animals [35], chemotherapy, or the process of 
BMT itself. Examination of skin in the immediate post-BMT 
period and correlation with larger numbers of pretransplant 
biopsies are presently under way to address the mechanisms of 
EDC depletion. 
In this study, 3 patients (#10, 12, and 15) did not receive 
fractionated total-body irradiation as a component of their 
conditioning regimen. Patient #12 had no EDC by 18 days after 
BMT; however, this patient had SCIDS, and to our knowledge, 
it has not as yet been determined whether these patients have 
detectable EDC prior to BMT. Patients #10 and 15 had aplastic 
anemia, and did not receive radiation pre-BMT. Patient #15 
was biopsied during the period (day 16) when depletion was 
most pronounced in our patient population. However, this 
patient showed normal numbers of EDC (10.1/mm pre-BMT 
and 12.3/mm at day 16). This suggests that cyclophosphamide 
and anti thymocyte serum are not responsible for EDC depletion 
and that addition of total-body irradiation results in the dis-
appearance of EDC characteristic of the early post-BMT pe-
riod. Perreault et al (19] have recently observed persistence of 
EDC after BMT in 2 patients with aplastic anemia treated with 
cyclophosphamide and total lymphoid irradiation, but not with 
total-body irradiation. Although some of their patients not 
treated with total-body irradiation did show low numbers of 
EDC after BMT, they also had low numbers pretransplant (day 
10), and it is difficult to determine from their data the true 
magnitude of depletion of EDC that occurred in this group. 
Recent data indicate that a subset of T6-positive EDC do 
not express HLA-DR antigen in normal [26] and diseased [36] 
~km . Because HLA-J?R represents a potential target antigen 
111 GVHD, we quantified T6/HLA-DR ratios in all biopsies. 
The ratio of T6/HLA-DR-positive cells, however, did not ap-
pear to correlate with clinical or histologic grades of GVHD. 
The rates of repopulation of EDC, however, did show a trend 
to be lower in individuals with severe clinical GVHD when 
compared to patients with lower clinical grades or without 
c!inical di~ease (e.g., patient #4) . This is consistent with pre-
viOus studies of human disease (19] and in animals (30]. Rates 
?f repoJ?ulation of EDC are likely to be determined by the 
mteractwn of a number of potential variables in both recipient 
and donor. For example, ongoing destruction or exodus of EDC 
possibly the result of GVHD, could partially counterbalanc~ 
influx of repopulating cells. Number and migratory function of 
donor EDC precursors in the transplanted marrow as well as 
the possible existence of local pools of precursor EDC not 
destroyed in the recipient may influence the kinetics of this 
influx. Further studies are necessary to clarify whether varia-
bility in rates of repopulation of EDC are related to host factors 
(e.g., underlying disease, debilitation), differences in reconsti -
tution of donor immunocompetent cells, or GVHD. 
At the present time, the kinetics of EDC in humans are 
unknown. Regardless of the mechanisms of EDC depletion 
human BMT may provide an important model for the study of 
these cellular events. Recently, the finding of common Ieuko-
c:yte antig_e~ on epidermal Langerhans cells [16,17] has pro-
VIded add1bonal support for the concept that in humans as 
in murine models, these cells derive from the bone mar~ow 
[14,15]. Borgaonkar et al have observed Y body fluorescence in 
hematopoietic cells in one female recipient of marrow from a 
male donor [37], and although not entirely specific for the Y 
chro~osome, this technique has recently been used to study 
EDC 111 the posttransplant setting [19,38). In addition tech-
nology is now possible to define the origin (donor vs h~st) of 
EDC using monoclonal antibodies directed against polymorphic 
MHC antigens in appropriate (haploidentical) BMT settings. 
Based upon the findings in this report, such studies in this 
clinically relevant patient population should provide new in-
sights into the pathobiology of EDC in humans. 
Mr. Richard Shepard provided valuable technical assistance and Ms. 
Mary Cook aided in preparation and typing of this manuscript. We are 
grateful to Dr. Jerome Ritz for providing biopsy material on pat ients 
#1 and 5. 
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